TRANSMAB
Technology platformBlood-brain-barrier-crossing antibody platform; reported to have been licensed to a global pharmaceutical company under a joint R&D and licensing agreement in February 2026.
FROM PUBLIC EVENTS · 2026-11-18
Early clinical · first deals Signed its first global licensing deal for a blood-brain-barrier-crossing antibody platform and is developing an Alzheimer's antibody in preclinical studies. Also seen: Discovery · preclinical
Roles often seen at this stageResearch & development · BD & licensing
A Suwon-based biotech founded in April 2019 that develops brain-disease treatments with TRANSMAB, its blood-brain-barrier-crossing antibody platform.
Blood-brain-barrier-crossing antibody platform; reported to have been licensed to a global pharmaceutical company under a joint R&D and licensing agreement in February 2026.
Preclinical antibody candidate for Alzheimer's disease that targets PD-L1 in the brain to restore immune balance.
Signed a joint R&D and licensing agreement for the TRANSMAB platform with a global pharmaceutical company.
Received an investment from Hyosung Ventures.
Ran its first new funding round in five years, with Intervest as anchor investor.
Official role guide
Observed 2026-11-18
Information from a role guide does not establish a current vacancy.
A brief based on selected official material, not an exhaustive product or vacancy list.